查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1631519

胃癌治療市場規模、佔有率、趨勢分析報告：依治療類型、疾病適應症、給藥途徑、藥物類別、地區、細分市場預測，2025-2030年

Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Standard Chemotherapy), By Disease Indication, By Route Of Administration, By Drug Class, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

胃癌治療市場的成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年全球胃癌治療市場規模將達到111.9億美元，預計2025年至2030年複合年成長率為12.5%。

免疫療法和分子標靶療法的推廣以及新藥的推出預計將推動成長。

據Globocan稱，2020年胃癌發生率約為110萬，預計2030年將增加至142萬。隨著我們對疾病分子基礎的了解增加，越來越多的標靶藥物和免疫療法藥物正在被開發並推向市場。Herceptin等 HER-2標靶藥物自 2010 年起就已上市。此外， CYRAMZA是一種針對 VEGF 的單株抗體，自 2014 年起已上市。目前正在開發針對 EGFR 和 PD-1 的藥物和免疫療法作為胃癌的治療方法。

臨床管線中藥物的核准和隨後的推出也有望推動胃癌治療市場。例如，2021年3月，NMPA在中國核准了禮來公司和信達生物製藥的PD-1抑制劑信迪利單抗在中國用於治療胃癌或胃食道連接部腺癌。此外，2020年5月，美國FDA將Enhertu指定為治療胃癌的孤兒藥。隨後，2021年1月，美國FDA核准Enhertz用於治療進行性或轉移性胃癌。

Herceptin等關鍵藥物的專利到期以及隨後生物學名藥的推出預計將抑制胃癌治療市場的成長。此外，由於高成本，標靶治療的採用率較低也可能阻礙市場成長。例如，與其他藥物相比， CYRAMZA被認為成本效益較低。在英國，它被 NICE 拒絕，因為它不符合成本效益。此外，由於與臨床相關比較者相比缺乏其他福利，法國拒絕報銷。

胃癌治療市場報告亮點

  • 標靶治療佔據市場主導地位，2024 年佔 39.6% 的佔有率。標靶治療精確靶向癌細胞，同時最大限度地減少對鄰近健康組織的傷害。
  • 2024年，胃癌/胃食道連接部以84.7%的銷售佔有率引領市場。
  • 注射療法由於其快速治療作用以及將化療和標靶治療直接注入血液的有效性，在 2024 年佔據最大的銷售佔有率，達到 89.0%。
  • VEGFR 拮抗劑由於在抑制腫瘤血管生成（腫瘤生長和轉移所必需的過程）方面發揮重要作用，將在 2024 年佔據重要的市場佔有率。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章胃癌治療市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章胃癌治療市場：依治療類型的業務分析

  • 治療類型市場佔有率，2024 年和 2030 年
  • 治療類型細分儀表板
  • 2018-2030 年按治療類型分類的市場規模、預測與趨勢分析
  • 標準化療
  • 標靶治療
  • 免疫療法

第5章胃癌治療市場：依疾病適應症進行業務分析

  • 2024年及2030年疾病適應症市場佔有率
  • 疾病指示細分儀表板
  • 2018-2030 年按疾病分類的市場規模、預測與趨勢分析
  • 胃癌/胃食道結合部癌
  • 胃腸道基質腫瘤

第6章胃癌治療市場：依給藥途徑進行的業務分析

  • 2024 年及 2030 年給藥途徑市場佔有率
  • 細分儀表板
  • 2018-2030 年按管理途徑分類的市場規模、預測與趨勢分析
  • 口服
  • 可注射的

第7章胃癌治療市場：藥物類別的業務分析

  • 2024 年及 2030 年藥品類別市場佔有率
  • 藥品類別細分儀表板
  • 2018-2030 年按藥物類別分類的市場規模、預測與趨勢分析
  • PD-1/PD-L1抑制劑
  • HER2拮抗劑
  • VEGFR拮抗劑
  • 其他

第8章 胃癌治療市場：區域估算及趨勢分析

  • 2024 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 參與者概覽
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • Novartis AG
    • Pfizer Inc.
    • Mylan NV
    • F. Hoffmann-La Roche Ltd
    • Eli Lilly and Company
    • Merck &Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • CELLTRION INC.
    • Samsung Bioepis
    • Bristol-Myers Squibb Company
Product Code: GVR-4-68039-973-9

Stomach Cancer Treatment Market Growth & Trends:

The global stomach cancer treatment market size is estimated to reach USD 11.19 billion by 2030, registering to grow at a CAGR of 12.5% from 2025 to 2030 according to a new report by Grand View Research, Inc. Increasing uptake of immunotherapy and targeted therapy, coupled with the launch of new drugs, is expected to fuel growth.

According to Globocan, the incidence of gastric cancer in 2020 was around 1.1 million, which is expected to increase to 1.42 million by 2030. Increasing knowledge regarding the molecular basis of the disease has led to a rise in the number of targeted drugs and immunotherapy drugs being developed and launched in the market. HER-2 targeted drugs such as Herceptin have been available in the market since 2010. Another targeted drug, Cyramza, which is a VEGF-targeting monoclonal antibody, has been available since 2014. EGFR and PD-1 targeted drugs and immunotherapies are currently being developed for the treatment of gastric cancer.

The approval and subsequent launch of drugs in the clinical pipeline are also expected to drive the gastric cancer therapy market. For instance, in March 2021, the NMPA approved Eli Lilly and Innovent Biologics' drug Sintilimab, a PD-1 inhibitor, for the treatment of gastric or gastroesophageal junction adenocarcinoma in China. Furthermore, in May 2020, the U.S. FDA granted the orphan drug designation to Enhertu for the treatment of gastric cancers. Subsequently, in January 2021, the U.S. FDA approved Enhertu for the treatment of advanced or metastatic forms of the disease.

Patent expiry of key drugs such as Herceptin and subsequent launch of biosimilars are expected to restrain the growth of the gastric cancer therapy market. Additionally, lesser adoption of targeted therapy due to high costs might hamper the growth of the market. For instance, Cyramza was not considered cost-effective as compared to other drugs. It was rejected by NICE due to a lack of cost-effectiveness in England. Furthermore, the product was rejected for reimbursement in France due to a lack of additional benefits compared to the clinically relevant comparators.

Stomach Cancer Treatment Market Report Highlights:

  • Targeted therapy dominated the market and accounted for a share of 39.6% in 2024. Targeted therapy offers precision targeting cancer cells while minimizing harm to adjacent healthy tissues.
  • Gastric cancer/gastroesophageal junction led the market with a revenue share of 84.7% in 2024, fueled by its considerable prevalence and associated mortality rates worldwide.
  • Injectable treatment held the largest revenue share of 89.0% in 2024, aided by their rapid therapeutic action and effectiveness in administering chemotherapy and targeted therapies directly into the bloodstream.
  • VEGFR antagonists held a substantial share in 2024 due to their critical role in inhibiting tumor angiogenesis, a vital process for tumor growth and metastasis.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment Type
    • 1.2.2. Disease Indication
    • 1.2.3. Route of Administration
    • 1.2.4. Drug Class
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Stomach Cancer Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Stomach Cancer Treatment Market: Treatment Type Business Analysis

  • 4.1. Treatment Type Market Share, 2024 & 2030
  • 4.2. Treatment Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2018 to 2030 (USD Million)
  • 4.4. Standard Chemotherapy
    • 4.4.1. Standard Chemotherapy Market, 2018 - 2030 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)

Chapter 5. Stomach Cancer Treatment Market: Disease Indication Business Analysis

  • 5.1. Disease Indication Market Share, 2024 & 2030
  • 5.2. Disease Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
  • 5.4. Gastric Cancer/Gastroesophageal Junction Cancer
    • 5.4.1. Gastric Cancer/Gastroesophageal Junction Cancer Market, 2018 - 2030 (USD Million)
  • 5.5. Gastrointestinal Stromal Tumors
    • 5.5.1. Gastrointestinal Stromal Tumors Market, 2018 - 2030 (USD Million)

Chapter 6. Stomach Cancer Treatment Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2030
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
  • 6.5. Injectable
    • 6.5.1. Injectable Market, 2018 - 2030 (USD Million)

Chapter 7. Stomach Cancer Treatment Market: Drug Class Business Analysis

  • 7.1. Drug Class Market Share, 2024 & 2030
  • 7.2. Drug Class Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 7.4. PD-1/PD-L1 Inhibitors
    • 7.4.1. PD-1/PD-L1 Inhibitors Market, 2018 - 2030 (USD Million)
  • 7.5. HER2 Antagonists
    • 7.5.1. HER2 Antagonists Market, 2018 - 2030 (USD Million)
  • 7.6. VEGFR Antagonists
    • 7.6.1. VEGFR Antagonists Market, 2018 - 2030 (USD Million)
  • 7.7 Others
    • 7.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Stomach Cancer Treatment Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novartis AG
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Pfizer Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Mylan N.V.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. F. Hoffmann-La Roche Ltd
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Eli Lilly and Company
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Merck & Co., Inc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Teva Pharmaceutical Industries Ltd.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. CELLTRION INC.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Samsung Bioepis
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Bristol-Myers Squibb Company
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global stomach cancer treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 5. Global stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 6. Global stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 7. Global stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 8. North America stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
  • Table 9. North America stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 10. North America stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 11. North America stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12. North America stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 13. U.S. stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 14. U.S. stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 15. U.S. stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16. U.S. stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 17. Canada stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 18. Canada stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 19. Canada stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 20. Canada stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 21. Mexico stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 22. Mexico stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 23. Mexico stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24. Mexico stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 25. Europe stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
  • Table 26. Europe stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 27. Europe stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 28. Europe stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 29. Europe stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 30. UK stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 31. UK stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 32. UK stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33. UK stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 34. Germany stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 35. Germany stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 36. Germany stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37. Germany stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 38. France stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 39. France stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 40. France stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41. France stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 42. Italy stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 43. Italy stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 44. Italy stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45. Italy stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 46. Spain stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 47. Spain stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 48. Spain stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49. Spain stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 50. Denmark stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 51. Denmark stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 52. Denmark stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 53. Denmark stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 54. Sweden stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 55. Sweden stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 56. Sweden stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57. Sweden stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 58. Norway stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 59. Norway stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 60. Norway stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61. Norway stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66. Asia Pacific stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 67. China stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 68. China stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 69. China stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70. China stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 71. Japan stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 72. Japan stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 73. Japan stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 74. Japan stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 75. India stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 76. India stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 77. India stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78. India stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 79. Australia stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 80. Australia stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 81. Australia stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82. Australia stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 83. South Korea stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 84. South Korea stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 85. South Korea stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86. South Korea stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 87. Thailand stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 88. Thailand stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 89. Thailand stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 90. Thailand stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 91. Latin America stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
  • Table 92. Latin America stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 93. Latin America stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 94. Latin America stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95. Latin America stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 96. Brazil stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 97. Brazil stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 98. Brazil stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 99. Brazil stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 100. Argentina stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 101. Argentina stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 102. Argentina stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 103. Argentina stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 104. Middle East & Africa Stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
  • Table 105. Middle East & Africa stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 106. Middle East & Africa stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 107. Middle East & Africa stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 108. Middle East & Africa stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 109. South Africa stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 110. South Africa stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 111. South Africa stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 112. South Africa stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 116. Saudi Arabia stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 117. UAE stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 118. UAE stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 119. UAE stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 120. UAE stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 121. Kuwait stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 122. Kuwait stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
  • Table 123. Kuwait stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 124. Kuwait stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Stomach cancer treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment type and disease indication outlook (USD Million)
  • Fig. 10 Route of administration and drug class outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Stomach cancer treatment market dynamics
  • Fig. 13 Stomach cancer treatment market: Porter's five forces analysis
  • Fig. 14 Stomach cancer treatment market: PESTLE analysis
  • Fig. 15 Others market, 2018 - 2030 (USD Million)
  • Fig. 16 Stomach cancer treatment market: Treatment type segment dashboard
  • Fig. 17 Stomach cancer treatment market: Treatment type market share analysis, 2024 & 2030
  • Fig. 18 Standard chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 20 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 21 Stomach cancer treatment market: Disease indication segment dashboard
  • Fig. 22 Stomach cancer treatment market: Disease indication market share analysis, 2024 & 2030
  • Fig. 23 Gastric cancer/gastroesophageal junction cancer market, 2018 - 2030 (USD Million)
  • Fig. 24 Gastrointestinal stromal tumors market, 2018 - 2030 (USD Million)
  • Fig. 25 Stomach cancer treatment market: Route of administration segment dashboard
  • Fig. 26 Stomach cancer treatment market: Route of administration market share analysis, 2024 & 2030
  • Fig. 27 Oral market, 2018 - 2030 (USD Million)
  • Fig. 28 Injectable market, 2018 - 2030 (USD Million)
  • Fig. 29 Stomach cancer treatment market: Drug class segment dashboard
  • Fig. 30 Stomach cancer treatment market: Drug class market share analysis, 2024 & 2030
  • Fig. 31 PD-1/PD-L1 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 32 HER2 antagonists market, 2018 - 2030 (USD Million)
  • Fig. 33 VEGFR antagonists market, 2018 - 2030 (USD Million)
  • Fig. 34 Stomach cancer treatment market revenue, by region
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 Regional marketplace: Key takeaways
  • Fig. 37 North America stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. country dynamics
  • Fig. 39 U.S. stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 Canada country dynamics
  • Fig. 41 Canada stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Mexico country dynamics
  • Fig. 43 Mexico stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Europe stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 UK country dynamics
  • Fig. 46 UK stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Germany country dynamics
  • Fig. 48 Germany stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 France country dynamics
  • Fig. 50 France stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Italy country dynamics
  • Fig. 52 Italy stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Spain country dynamics
  • Fig. 54 Spain stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 Norway country dynamics
  • Fig. 56 Norway stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden country dynamics
  • Fig. 58 Sweden stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 Denmark country dynamics
  • Fig. 60 Denmark stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 Japan country dynamics
  • Fig. 63 Japan stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 64 China country dynamics
  • Fig. 65 China stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 66 India country dynamics
  • Fig. 67 India stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 68 Australia country dynamics
  • Fig. 69 Australia stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea country dynamics
  • Fig. 71 South Korea stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand country dynamics
  • Fig. 73 Thailand stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 Latin America stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 75 Brazil country dynamics
  • Fig. 76 Brazil stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 77 Argentina country dynamics
  • Fig. 78 Argentina stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 79 MEA stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 80 South Africa country dynamics
  • Fig. 81 South Africa stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 82 Saudi Arabia country dynamics
  • Fig. 83 Saudi Arabia stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 84 UAE country dynamics
  • Fig. 85 UAE stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 86 Kuwait country dynamics
  • Fig. 87 Kuwait stomach cancer treatment market, 2018 - 2030 (USD Million)
  • Fig. 88 Company categorization
  • Fig. 89 Company market position analysis
  • Fig. 90 Strategic framework